|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CRABP2 |
Gene summary for CRABP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CRABP2 | Gene ID | 1382 |
| Gene name | cellular retinoic acid binding protein 2 | |
| Gene Alias | CRABP-II | |
| Cytomap | 1q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P29373 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1382 | CRABP2 | P4T-E | Human | Esophagus | ESCC | 2.92e-32 | 1.62e+00 | 0.1323 |
| 1382 | CRABP2 | P5T-E | Human | Esophagus | ESCC | 3.74e-17 | 9.49e-01 | 0.1327 |
| 1382 | CRABP2 | P8T-E | Human | Esophagus | ESCC | 1.74e-44 | 2.01e+00 | 0.0889 |
| 1382 | CRABP2 | P9T-E | Human | Esophagus | ESCC | 4.57e-04 | 8.16e-01 | 0.1131 |
| 1382 | CRABP2 | P10T-E | Human | Esophagus | ESCC | 4.86e-73 | 2.03e+00 | 0.116 |
| 1382 | CRABP2 | P11T-E | Human | Esophagus | ESCC | 1.01e-10 | 2.05e+00 | 0.1426 |
| 1382 | CRABP2 | P12T-E | Human | Esophagus | ESCC | 1.95e-47 | 1.34e+00 | 0.1122 |
| 1382 | CRABP2 | P15T-E | Human | Esophagus | ESCC | 8.34e-14 | 8.30e-01 | 0.1149 |
| 1382 | CRABP2 | P16T-E | Human | Esophagus | ESCC | 3.56e-08 | 4.16e-01 | 0.1153 |
| 1382 | CRABP2 | P17T-E | Human | Esophagus | ESCC | 2.88e-11 | 1.11e+00 | 0.1278 |
| 1382 | CRABP2 | P22T-E | Human | Esophagus | ESCC | 5.89e-65 | 1.83e+00 | 0.1236 |
| 1382 | CRABP2 | P23T-E | Human | Esophagus | ESCC | 6.39e-07 | 8.85e-01 | 0.108 |
| 1382 | CRABP2 | P24T-E | Human | Esophagus | ESCC | 3.53e-08 | 5.90e-01 | 0.1287 |
| 1382 | CRABP2 | P26T-E | Human | Esophagus | ESCC | 5.23e-108 | 2.61e+00 | 0.1276 |
| 1382 | CRABP2 | P27T-E | Human | Esophagus | ESCC | 1.39e-10 | 7.06e-01 | 0.1055 |
| 1382 | CRABP2 | P28T-E | Human | Esophagus | ESCC | 7.80e-03 | 4.03e-01 | 0.1149 |
| 1382 | CRABP2 | P31T-E | Human | Esophagus | ESCC | 3.02e-43 | 1.40e+00 | 0.1251 |
| 1382 | CRABP2 | P36T-E | Human | Esophagus | ESCC | 2.12e-27 | 2.35e+00 | 0.1187 |
| 1382 | CRABP2 | P37T-E | Human | Esophagus | ESCC | 3.19e-48 | 1.66e+00 | 0.1371 |
| 1382 | CRABP2 | P38T-E | Human | Esophagus | ESCC | 4.66e-18 | 1.48e+00 | 0.127 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00085445 | Breast | Precancer | epidermis development | 35/1080 | 324/18723 | 2.71e-04 | 3.96e-03 | 35 |
| GO:00160497 | Breast | Precancer | cell growth | 46/1080 | 482/18723 | 5.63e-04 | 7.16e-03 | 46 |
| GO:00015587 | Breast | Precancer | regulation of cell growth | 39/1080 | 414/18723 | 1.81e-03 | 1.78e-02 | 39 |
| GO:000854412 | Breast | IDC | epidermis development | 41/1434 | 324/18723 | 1.03e-03 | 1.14e-02 | 41 |
| GO:001604913 | Breast | IDC | cell growth | 56/1434 | 482/18723 | 1.16e-03 | 1.26e-02 | 56 |
| GO:000155813 | Breast | IDC | regulation of cell growth | 49/1434 | 414/18723 | 1.55e-03 | 1.55e-02 | 49 |
| GO:00325358 | Breast | IDC | regulation of cellular component size | 45/1434 | 383/18723 | 2.72e-03 | 2.41e-02 | 45 |
| GO:000854422 | Breast | DCIS | epidermis development | 40/1390 | 324/18723 | 1.05e-03 | 1.16e-02 | 40 |
| GO:001604923 | Breast | DCIS | cell growth | 54/1390 | 482/18723 | 1.60e-03 | 1.59e-02 | 54 |
| GO:000155822 | Breast | DCIS | regulation of cell growth | 47/1390 | 414/18723 | 2.39e-03 | 2.16e-02 | 47 |
| GO:003253514 | Breast | DCIS | regulation of cellular component size | 44/1390 | 383/18723 | 2.58e-03 | 2.30e-02 | 44 |
| GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
| GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
| GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
| GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
| GO:00160498 | Cervix | CC | cell growth | 92/2311 | 482/18723 | 1.16e-05 | 2.49e-04 | 92 |
| GO:00325359 | Cervix | CC | regulation of cellular component size | 76/2311 | 383/18723 | 1.66e-05 | 3.21e-04 | 76 |
| GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
| GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
| GO:00459277 | Cervix | CC | positive regulation of growth | 53/2311 | 259/18723 | 1.33e-04 | 1.64e-03 | 53 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CRABP2 | SNV | Missense_Mutation | novel | c.379G>A | p.Asp127Asn | p.D127N | P29373 | protein_coding | tolerated(0.07) | probably_damaging(0.924) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
| CRABP2 | SNV | Missense_Mutation | rs757917252 | c.412G>C | p.Glu138Gln | p.E138Q | P29373 | protein_coding | tolerated(0.09) | benign(0.042) | TCGA-DY-A1DC-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Chemotherapy | capecitabine | PR |
| CRABP2 | SNV | Missense_Mutation | novel | c.124N>A | p.Val42Met | p.V42M | P29373 | protein_coding | deleterious(0.03) | probably_damaging(0.981) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CRABP2 | SNV | Missense_Mutation | c.98N>A | p.Ala33Asp | p.A33D | P29373 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| CRABP2 | SNV | Missense_Mutation | rs548565052 | c.179G>A | p.Arg60His | p.R60H | P29373 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD |
| CRABP2 | SNV | Missense_Mutation | c.51N>T | p.Glu17Asp | p.E17D | P29373 | protein_coding | tolerated(0.35) | benign(0.003) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CRABP2 | SNV | Missense_Mutation | novel | c.317C>T | p.Pro106Leu | p.P106L | P29373 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| CRABP2 | SNV | Missense_Mutation | rs548565052 | c.179G>A | p.Arg60His | p.R60H | P29373 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-D1-A163-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
| CRABP2 | SNV | Missense_Mutation | novel | c.13N>C | p.Ser5Pro | p.S5P | P29373 | protein_coding | deleterious(0.01) | possibly_damaging(0.81) | TCGA-D1-A2G0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CRABP2 | SNV | Missense_Mutation | novel | c.92A>T | p.Lys31Met | p.K31M | P29373 | protein_coding | deleterious(0.04) | possibly_damaging(0.449) | TCGA-CC-A5UD-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1382 | CRABP2 | NA | RETINOID | 12153175 | ||
| 1382 | CRABP2 | NA | BESTATIN METHYL ESTER | BESTATIN METHYL ESTER | 21515062 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |